Sandoz’ Ziextenzo And Riximyo Cleared In Canada
Company Has Portfolio Of Five Biosimilars Planned For 2021
Executive Summary
Sandoz Canada is looking to bolster its portfolio of biosimilars after obtaining marketing authorizations for both pegfilgrastim and rituximab.